This database contains 140 studies, archived under the term: "UK"
Click here to filter this large number of results.
REMCARE: reminiscence groups for people with dementia and their family caregivers – effectiveness and cost-effectiveness pragmatic multicentre randomised trial
Woods, R. T.,
Bruce, E.,
Edwards, R. T.,
Elvish, R.,
Hoare, Z.,
Hounsome, B.,
Keady, J.,
Moniz-Cook, E. D.,
Orgeta, V.,
Orrell, M.,
Rees, J.,
Russell, I. T.
Objectives: The aim of the REMiniscence groups for people with dementia and their family CAREgivers (REMCARE) study was to assess the effectiveness and cost-effectiveness of joint reminiscence groups for people with dementia and their family caregivers as compared with usual care.; Design: A multicentre, pragmatic randomised controlled trial with two parallel arms – an intervention […]
Is gardening a stimulating activity for people with advanced Huntington’s disease?
This study evaluated adapted gardening as an activity for people with advanced Huntington’s disease (HD) and explored its therapeutic aspects. Visitors and staff completed a questionnaire and participated in structured interviews to capture further information, whereas a pictorial questionnaire was designed for residents with communication difficulties. Staff reported that gardening was a constructive, outdoor activity […]
Toward onset prevention of cognitive decline in adults with Down syndrome (the TOP-COG study): study protocol for a randomized controlled trial
Cooper, Sally-Ann,
Caslake, Muriel,
Evans, Jonathan,
Hassiotis, Angela,
Jahoda, Andrew,
McConnachie, Alex,
Morrison, Jill,
Ring, Howard,
Starr, John,
Stiles, Ciara,
Sullivan, Frank
Background: Early-onset dementia is common in Down syndrome adults, who have trisomy 21. The amyloid precursor protein gene is on chromosome 21, and so is over-expressed in Down syndrome, leading to amyloid β (Aβ) over-production, a major upstream pathway leading to Alzheimer disease (AD). Statins (microsomal 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors), have pleiotropic effects including […]
Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial
Emre, Murat,
Tsolaki, Magda,
Bonuccelli, Ubaldo,
Destée, Alain,
Tolosa, Eduardo,
Kutzelnigg, Alexandra,
Ceballos-Baumann, Andrés,
Zdravkovic, Slobodan,
Bladström, Anna,
Jones, Roy
Background: Previous studies have suggested that patients with Lewy-body-related dementias might benefit from treatment with the N-methyl D-aspartate receptor antagonist memantine, but further data are needed. Therefore, the efficacy and safety of memantine were investigated in patients with mild to moderate Parkinson’s disease dementia (PDD) or dementia with Lewy bodies (DLB).; Methods: Patients (≥50 years […]
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Rinne, Juha O.,
Brooks, David J.,
Rossor, Martin N.,
Fox, Nick C.,
Bullock, Roger,
Klunk, William E.,
Mathis, Chester A.,
Blennow, Kaj,
Barakos, Jerome,
Okello, Aren A.,
Rodriguez Martinez de Liano, Sofia,
Liu, Enchi,
Koller, Martin,
Gregg, Keith M.,
Schenk, Dale,
Black, Ronald,
Grundman, Michael
Background: Carbon-11-labelled Pittsburgh compound B ((11)C-PiB) PET is a marker of cortical fibrillar amyloid-beta load in vivo. We used (11)C-PiB PET to investigate whether bapineuzumab, a humanised anti-amyloid-beta monoclonal antibody, would reduce cortical fibrillar amyloid-beta load in patients with Alzheimer’s disease.; Methods: Patients with mild-to-moderate Alzheimer’s disease were randomly assigned to receive intravenous bapineuzumab or […]
Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer’s disease
Maher-Edwards, G.,
Zvartau-Hind, M.,
Hunter, A. J.,
Gold, M.,
Hopton, G.,
Jacobs, G.,
Davy, M.,
Williams, P.
Background: This randomized, double-blind, placebo-controlled study investigated the efficacy and tolerability of the 5-HT6 receptor antagonist, SB-742457, in subjects with mild-to-moderate probable Alzheimer’s disease (AD).; Methods: Participating subjects had a Mini-Mental State Examination (MMSE) score of 12 to 26 after a 4-week, single-blind, placebo run-in phase, and were randomized (2:1:1:2) to receive placebo, SB-742457 5 […]
A multi-center randomized proof-of-concept clinical trial applying ¹⁸FFDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer’s disease
Tzimopoulou, Sofia,
Cunningham, Vincent J.,
Nichols, Thomas E.,
Searle, Graham,
Bird, Nick P.,
Mistry, Prafull,
Dixon, Ian J.,
Hallett, William A.,
Whitcher, Brandon,
Brown, Andrew P.,
Zvartau-Hind, Marina,
Lotay, Narinder,
Lai, Robert Y. K.,
Castiglia, Mary,
Jeter, Barbara,
Matthews, Julian C.,
Chen, Kewei,
Bandy, Dan,
Reiman, Eric M.,
Gold, Michael,
Rabiner, Eugenii A.,
Matthews, Paul M.
Here we report the first multi-center clinical trial in Alzheimer’s disease (AD) using fluorodeoxyglucose positron emission tomography ([18F]FDG-PET) measures of brain glucose metabolism as the primary outcome. We contrasted effects of 12 months treatment with the PPARγ agonist Rosiglitazone XR versus placebo in 80 mild to moderate AD patients. Secondary objectives included testing for reduction […]